Journals / Anatolian Current Medical Journal / 2026 / Volume: 8 Issue: 6

Impact of nutritional status on health-related quality of life in patients with multiple myeloma: a cross-sectional study

Neslihan Kayahan(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DR. ABDURRAHMAN YURTASLAN ONKOLOJİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, GERİATRİ BİLİM DALI)0000-0002-6802-7926
Pages
—
Publication Date
2026-10-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Routine nutritional screening using the MNA-SF may facilitate early identification of patients at risk for functional decline and impaired quality of life, supporting individualized supportive care.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: To investigate the association between nutritional status and health-related quality of life (HRQoL) in patients with multiple myeloma (MM) using validated nutritional and disease-specific quality-of-life instruments.
📊
Key Findings & Data:Methods: This single-center cross-sectional study included 67 adult patients with MM.
💡
Conclusion & Impact:Routine nutritional screening using the MNA-SF may facilitate early identification of patients at risk for functional decline and impaired quality of life, supporting individualized supportive care.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Multiple myeloma · quality of life · nutritional status

Abstract

Aims: To investigate the association between nutritional status and health-related quality of life (HRQoL) in patients with multiple myeloma (MM) using validated nutritional and disease-specific quality-of-life instruments. Methods: This single-center cross-sectional study included 67 adult patients with MM. Nutritional status was assessed using the Mini Nutritional Assessment-Short Form (MNA-SF). HRQoL was evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the EORTC QLQ-MY20 module. Group comparisons, Spearman correlation, and multivariable linear regression analyses adjusted for clinically relevant covariates were performed. Results: The median MNA-SF score was 10 (IQR, 8-13); 37.3% of patients had normal nutritional status, 40.3% were at risk of malnutrition, and 22.4% were malnourished. Poorer nutritional status was associated with significantly lower Global Health Status and worse physical, role, emotional, cognitive, and social functioning (all p≤0.001). Symptom burden increased significantly with worsening nutritional status. MNA-SF scores correlated positively with Global Health Status (ρ=0.296, p=0.015) and remained independently associated with Global Health Status after adjustment for ECOG performance status, hemoglobin level, treatment status, disease duration, body mass-index, and serum albumin (β=2.19, 95% CI 0.58-3.81; p=0.008). Conclusion: Impaired nutritional status was independently associated with poorer HRQoL in patients with MM. Routine nutritional screening using the MNA-SF may facilitate early identification of patients at risk for functional decline and impaired quality of life, supporting individualized supportive care.

🔖

Cite This Article

Giden, A. O., Kayahan, N. (2026). Impact of nutritional status on health-related quality of life in patients with multiple myeloma: a cross-sectional study. Anatolian Current Medical Journal, Volume: 8 Issue: 6. https://ajindex.com/articles/1667862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (26)

  1. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802-1824. doi:10.1002/ajh.27422
  2. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322. doi:10.1016/j.annonc.2020.11.014
  3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520. doi:10.1182/blood-2007-10-116129
  4. Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97(5):416-429. doi:10.1111/ejh.12790
  5. Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27(10):1959-1969. doi:10.1038/leu.2013.185
  6. Forde K, Cocks K, Wells JR, McMillan I, Kyriakou C; EORTC Quality of Life Group. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development. Blood Cancer J. 2023;13(1):79. doi:10.1038/s41408-023-00815-9
  7. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898-2913. doi:10.1016/j.clnu.2021.02.005
  8. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48. doi:10.1016/j.clnu.2016.07.015
  9. Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition-a consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1-9. doi:10.1016/j.clnu.2018.08.002
  10. Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form Mini-Nutritional Assessment (MNA-SF). J Gerontol A Biol Sci Med Sci. 2001; 56(6):M366-M372. doi:10.1093/gerona/56.6.m366
  11. Vellas B, Villars H, Abellan G, et al. Overview of the MNA-its history and challenges. J Nutr Health Aging. 2006;10(6):456-465.
  12. Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging. 2009;13(9):782-788. doi:10.1007/s12603-009-0214-7
  13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. doi:10.1093/jnci/85.5.365
  14. Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670-1678. doi:10.1016/j.ejca.2007.04.022
  15. Velikova G, Coens C, Efficace F, et al. Health-related quality of life in EORTC clinical trials: 30 years of progress from methodological developments to making a real impact on oncology practice. Eur J Cancer Suppl. 2012;10(1):141-149. doi:10.1016/S1359-6349(12)70023-X
  16. Husson O, de Rooij BH, Kieffer J, et al. The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the "real-world": results from the population-based PROFILES registry. Oncologist. 2020;25(4):e722-e732. doi:10.1634/theoncologist.2019-0348
  17. Torbahn G, Strauss T, Sieber CC, Kiesswetter E, Volkert D. Nutritional status according to the Mini Nutritional Assessment (MNA)® as potential prognostic factor for health and treatment outcomes in patients with cancer-a systematic review. BMC Cancer. 2020;20(1):594. doi:10.1186/s12885-020-07052-4
  18. Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: current practices and advances. Cancer Treat Res Commun. 2021;29:100476. doi:10.1016/j.ctarc.2021.100476
  19. Wang T, Lu Q, Tang L. Assessment tools for patient-reported outcomes in multiple myeloma. Support Care Cancer. 2023;31(7):431. doi:10.1007/s00520-023-07902-4
  20. Shapiro YN, Peppercorn JM, Yee AJ, Branagan AR, Raje NS, Donnell EKO. Lifestyle considerations in multiple myeloma. Blood Cancer J. 2021;11(10):172. doi:10.1038/s41408-021-00560-x
  21. Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40. doi:10.1038/s41408-021-00432-4
  22. Murugappan MN, King-Kallimanis BL, Bhatnagar V, et al. Measuring frailty using patient-reported outcomes (PRO) data: a feasibility study in patients with multiple myeloma. Qual Life Res. 2023;32(8):2281-2292. doi:10.1007/s11136-023-03390-5
  23. Efficace F, Gaidano G, Petrucci MT, et al. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Lancet Healthy Longev. 2022;3(9): e628-e635. doi:10.1016/S2666-7568(22)00172-6
  24. Lipof JJ, Abdallah N, Lipe B. Personalized treatment of multiple myeloma in frail patients. Curr Oncol Rep. 2024;26(7):744-753. doi:10.1007/s11912-024-01545-2
  25. Goodhew RE, Edwards BA. The effect of exercise interventions on quality of life in patients with multiple myeloma: a systematic review and meta-analysis of randomised controlled trials. Clin Exp Med. 2023; 23(7):3217-3230. doi:10.1007/s10238-023-01058-5
  26. Sarikaya D, Halil M, Kuyumcu ME, et al. Mini Nutritional Assessment test long and short form are valid screening tools in Turkish older adults. Arch Gerontol Geriatr. 2015;61(1):56-60. doi:10.1016/j.archger.2015.04.006